Darrell Etherington March 13, 2020
The U.S. Food and Drug Administration has granted emergency approval for use of a new test that can increase the rate of testing patients by up to 10 times compared to methods in use currently, Bloomberg reports. That speed improvement refers specifically to the technical capabilities of the testing process, meaning access to testing is still a separate issue, but it is the first commercially available test that has received emergency approval and for which equipment exists in fairly high volume across the U.S.
Testing is a core component of the effort to combat and control the spread of COVID-19, since those affected by the virus display a wide range of symptoms, and many could be carriers with only very mild external signs of the disease. Having effective and broadly available testing methods, that can test a high volume of patients per day, is a key part of any defense strategy since it means more effectively identifying the scope of affected populations and reinforcing the need for mitigation strategies like social isolation and distancing.
These new tests granted emergency approval can test up to 1,440 patients per day on an earlier generation of Roche’s testing hardware, or as many as 4,128 on a later iteration. Bloomberg notes that there are roughly 110 of these machines across both generations available in the U.S., and that more are being installed in “significant” volume in recent weeks as response efforts ramp up. These tests use analysis of patient saliva and mucus to determine if a patient has contracted a known coronavirus strain.
Access to coronavirus testing in the U.S. has been heavily criticized by healthcare professionals and experts to date, including at a congressional hearing this week. Observers have noted that countries that seem to have been able to bend the exponential curve of infection, including South Korea, China and Japan, have all done so in part supported by excellent and widespread testing available in high volume. This newly approved test should help private labs increase the availability of testing in the U.S., but it’s not yet clear exactly how that will play out in terms of the actual rate of U.S. patient testing in practice.
Successful Trading is the art of minimizing long term risk and maximizing capital allocation.
Recent RHHBY News
- Roche's Cancer Injection Tecentriq SC Gets European Commission Approval • Dow Jones News • 01/16/2024 06:49:00 AM
- Beyond Diabetes, a Blockbuster Horizon Beckons • InvestorsHub NewsWire • 01/10/2024 01:45:00 PM
- LumiraDx Agrees to Sell Point-of-Care Tech Platform to Roche • Dow Jones News • 12/29/2023 10:07:00 PM
- Roche's Xolair Granted FDA Priority Review • Dow Jones News • 12/19/2023 03:27:00 PM
- Poseida Therapeutics Shares Climb on Positive Data for Blood Cancer Treatment • Dow Jones News • 12/11/2023 03:31:00 PM
- Roche Obtains Positive Data on Early-Stage Breast Cancer Treatment • Dow Jones News • 12/08/2023 05:56:00 PM
- Roche's Inavolisib Breast Cancer Drug Gets Positive Results • Dow Jones News • 12/08/2023 05:38:00 PM
- Merck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage Trials • Dow Jones News • 12/06/2023 10:14:00 AM
- Roche's Inavolisib Breast Cancer Drug Shows Promise in Late-Stage Study • Dow Jones News • 12/05/2023 06:54:00 AM
- Trending: Roche to Buy Carmot Therapeutics in Deal Worth Up to $3.1 Billion • Dow Jones News • 12/04/2023 03:12:00 PM
- Roche to Buy Carmot Therapeutics for Up to $3.1 Billion in Bet on Obesity Treatments -- Update • Dow Jones News • 12/04/2023 11:34:00 AM
- Alaska Air Acquires Hawaiian Holdings, Spotify Cuts 1,500 Jobs, Uber’s S&P 500 Entry, and More • IH Market News • 12/04/2023 10:55:07 AM
- Roche Strikes Deal to Buy Drug Developer Carmot Therapeutics for $2.7 Billion • Dow Jones News • 12/04/2023 06:47:00 AM
- Roche's Genentech, Nvidia Team Up to Accelerate Drug Discovery With AI • Dow Jones News • 11/21/2023 04:06:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/07/2023 10:14:35 PM
- Roche Says Late-Stage Muscular Dystrophy Trial Didn't Meet Main Goal • Dow Jones News • 10/31/2023 06:26:00 AM
- Roche Gets FDA Approval for Vabysmo as Retinal Vein Occlusion Treatment • Dow Jones News • 10/27/2023 05:40:00 AM
- Trending: Roche to Buy Telavant From Roivant and Pfizer • Dow Jones News • 10/23/2023 07:41:00 PM
- Roche to Buy Telavant From Roivant, Pfizer in Deal Worth Up to $7.25 Billion -- Update • Dow Jones News • 10/23/2023 08:16:00 AM
- Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Billion Deal • Dow Jones News • 10/23/2023 05:50:00 AM
- Roche Shares Fall on Lower Sales Due to Currency Hit • Dow Jones News • 10/19/2023 09:55:00 AM
- Roche Backs Guidance After Sales Fall • Dow Jones News • 10/19/2023 05:48:00 AM
- Roche Lung Cancer Drug Reduced Risk of Recurrence, Death in Late-Stage Trial • Dow Jones News • 10/18/2023 06:14:00 AM
- Roche's Elecsys IL-6 Test Approved for Diagnosis of Neonatal Sepsis • Dow Jones News • 10/18/2023 05:54:00 AM
- AbbVie: Phase 3 Venetoclax/Dexamethasone Study Falls Short in Multiple Myeloma • Dow Jones News • 09/29/2023 12:15:00 PM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM